The U.S. Food and Drug Administration (FDA) is set to reconsider its decision regarding a treatment for a rare cancer after an unexpected rejection sparked controversy. The move comes amid growing scrutiny over potential political interference in drug approval processes.
In a separate development, the Trump administration has announced massive projected savings from its still-secret drug pricing deals. However, outside experts have raised concerns about the lack of transparency, stating that there is little way to independently verify the claimed savings.
The FDA’s reconsideration follows fresh accusations of political interference in drug reviews, which have intensified debates over the agency’s independence and decision-making processes.
Meanwhile, AI oncology startups are pioneering new approaches to cancer care by leveraging virtual platforms to improve patient outcomes and accessibility. These innovations aim to transform how cancer is diagnosed, monitored, and treated in the digital age.
In a parallel scientific breakthrough, researchers are exploring an entirely new frontier in biology—the “dark proteome”. This previously uncharted area of study could unlock critical insights into cellular functions and disease mechanisms, potentially revolutionizing our understanding of biology and medicine.
Related articles
STAT+: FDA drug center head Tracy Beth Høeg leaves as agency faces leadership vacuum
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Kennedy Swaps Vaccine Rhetoric for Story Time but Can’t Quite Change the Subject
Here in Washington, we’ve been hearing about tensions between the White House and one of its most controversial — but, at least in some circles, most...
Kratom use is on the rise in the US
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
STAT+: A political contest in the U.K. could shake up drug pricing
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-order abortion pills are legal (for now)
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...